A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink
Cristina Rebordosa, 1 Estel Plana, 1 Annalisa Rubino, 2 Jaume Aguado, 1 Alejhandra Lei, 3 Sami Daoud, 4 Nuria Saigi-Morgui, 1 Susana Perez-Gutthann, 1 Elena Rivero-Ferrer 1 1RTI Health Solutions, Barcelona, Spain; 2Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK; 3Patient Saf...
Main Authors: | Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-05-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/a-cohort-study-to-evaluate-the-risk-of-hospitalisation-for-congestive--peer-reviewed-fulltext-article-COPD |
Similar Items
-
Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01) -
AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01) -
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
by: D'Urzo AD, et al.
Published: (2019-02-01) -
The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
by: Wise RA, et al.
Published: (2021-03-01) -
New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016-02-01)